BRD4 and acute myeloid leukemia: Our results suggest that the short variant of BRD4 is a biological determinant of MDS phenotype and aggressiveness, since the two MDS subtypes (with lower and higher blast percentages) and AML patients exhibited overexpression of BRD4S, but particularly those with higher-risk disease.